Lin Liwei Lorraine
Transaction: 07/08/2026
BUY
Change
+254,780
Price
$1.93
Filing
07/10/2026
Type
BUY
NovaBridge Biosciences
NBP • Biotechnology
$1.80
— 0.00 (0.00%)
Current price
EarningsLatest report: Dec 31, 2025
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$90.30M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 8.09Negative growth trendWeak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Apr 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.80
Change0.00%
Shares Out50.17M
Market Cap$90.30M
Enterprise Value$60.16M
52W Range1.46 - 6.79
Beta1.45
P/E-4.54
P/B2.74
P/FCF-62.28
EV/EBITDA-1.91
EV/FCF-41.49
Price$1.80
Change0.00%
Shares Out50.17M
Market Cap$90.30M
Enterprise Value$60.16M
52W Range1.46 - 6.79
Beta1.45
P/E-4.54
P/B2.74
P/FCF-62.28
EV/EBITDA-1.91
EV/FCF-41.49
Earnings Yield-22.02%
FCF Yield-1.61%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.01
Current Ratio8.09
Quick Ratio8.09
Revenue 5Y-100.00%
Target$9.00
Target Upside400.00%
Target Median$9.00
Target Range9.00 - 9.00
Volume6.96K
Avg Volume708.69K
EPS Surprise-0.03
Investment DNA
How strong this company looks for long-term investors
36
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
62/100
Why this score▼
Manageable debt level · 0.01Healthy liquidity · 8.09Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 11 analyst votes · 2026-09-05
100/100
Bullish
Bullish
11
Hold
0
Bearish
0
Price Target
2026-07-31
Low
$9.00
Mean
$9.00
Median
$9.00
High
$9.00
Insider Transactions
Recent executive and insider activity
Hagler Mark Arnold
Transaction: 07/08/2026
BUY
Change
+949,050
Price
$1.93
Filing
07/10/2026
Type
BUY
Gupta Srishti
Transaction: 07/06/2026
BUY
Change
+3,000,000
Price
$2.01
Filing
07/08/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Lin Liwei Lorraine | BUY | +254,780 | $1.93 | 07/08/2026 | 07/10/2026 |
| Hagler Mark Arnold | BUY | +949,050 | $1.93 | 07/08/2026 | 07/10/2026 |
| Gupta Srishti | BUY | +3,000,000 | $2.01 | 07/06/2026 | 07/08/2026 |
| Gupta Srishti | OTHER | 0 | Not reported | 07/01/2026 | 07/08/2026 |
| Xu Cong Claire | SELL | -4,485 | $0.89 | 07/06/2026 | 07/07/2026 |
| Xu Cong Claire | SELL | -5,405 | Not reported | 07/04/2026 | 07/07/2026 |
| Xu Cong Claire | BUY | +12,432 | Not reported | 07/04/2026 | 07/07/2026 |
| Fu Wei | BUY | +1,010,100 | Not reported | 06/29/2026 | 06/30/2026 |
| Fu Wei | BUY | +725,140 | $2.45 | 06/29/2026 | 06/30/2026 |
| Cao Sean Wuxiong | BUY | +181,280 | Not reported | 06/22/2026 | 06/24/2026 |
| Cao Sean Wuxiong | BUY | +181,290 | $1.53 | 06/22/2026 | 06/24/2026 |
| Dennis Phillip Andrew | SELL | -8,494 | $0.66 | 06/18/2026 | 06/22/2026 |
| Dennis Phillip Andrew | SELL | -10,302 | Not reported | 06/17/2026 | 06/22/2026 |
| Dennis Phillip Andrew | BUY | +23,695 | Not reported | 06/17/2026 | 06/22/2026 |
| Xu Cong Claire | SELL | -3,494 | $3.94 | 06/01/2026 | 06/02/2026 |
| Xu Cong Claire | SELL | -4,079 | Not reported | 05/30/2026 | 06/02/2026 |
| Xu Cong Claire | BUY | +9,382 | Not reported | 05/30/2026 | 06/02/2026 |
| Cao Sean Wuxiong | SELL | -21,399 | $1.99 | 05/14/2026 | 05/18/2026 |
| Hagler Mark Arnold | BUY | +230,000 | $2.51 | 04/24/2026 | 04/28/2026 |
| Hagler Mark Arnold | OTHER | 0 | Not reported | 04/17/2026 | 04/22/2026 |